celares GmbH joined the Biosynth Group in July 2023 and became Biosynth GmbH in November 2023. We are recognized as the leaders in PEGylation services including process development, analytical characterization of PEG conjugates and manufacturing of activated PEGs for almost two decades. Recently, we extended our core competences to ‘bioconjugation’ and to ‘polymers for drug delivery’ in a more general sense, while maintaining PEGs and PEGylation as part of our extended services. Most recently, we were inspected by the local authorities and received GMP certificates for the release analytics of drug substances and for the manufacturing of conjugate vaccines. In addition, we have developed novel multimerization technologies that will benefit the developments of our customers and we offer these technologies in reasonable license agreements.
